Suresh S. Ramalingam, MD, has been named Executive Director of Winship Cancer Institute of Emory University. An internationally renowned thoracic oncologist and physician-scientist, Dr. Ramalingam has served as Winship’s Deputy Director since 2016. He began his new post on July 1.
Dr. Ramalingam takes the helm at a transformational moment for Winship, Georgia’s only National Cancer Institute (NCI)-designated comprehensive cancer center. He will preside over the largest expansion in Winship’s history, including the construction and opening of a new 17-story cancer facility on the campus of Emory University Hospital Midtown. He will also lead Winship as it seeks renewal of its NCI designation.
Suresh S. Ramalingam, MD
As Executive Director, Dr. Ramalingam will continue to lead efforts to extend local access to cancer research and care at Emory Healthcare’s six hospitals throughout metro Atlanta, Grady Memorial Hospital, Atlanta VA Medical Center, and Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta.
Dr. Ramalingam’s research has focused on the development of individualized therapies for patients with non–small cell lung cancer. He is principal investigator for Winship’s Lung Cancer SPORE, an NCI specialized program of research excellence; has published more than 200 peer-reviewed studies; and served as President of the Georgia Society of Clinical Oncology. Dr. Ramalingam also led the integration of Winship’s research, clinical, and educational components.
“I am deeply honored by the trust placed in me to lead Winship,” said Dr. Ramalingam. “With its exceptional researchers, physicians, nurses, and staff, Winship is well positioned to make seminal contributions to improving the lives of … patients everywhere. Together, we will continue to build Winship’s eminence as a destination cancer center, and we will remain steadfast in our dedication to accelerating cures and inspiring hope.”
In addition to his Winship duties, Dr. Ramalingam serves as Assistant Dean for Cancer Research at Emory University School of Medicine, where he is also Professor of Hematology and Medical Oncology, Director of the Division of Medical Oncology, and the Roberto C. Goizueta Distinguished Chair for Cancer Research.
